Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

CompletedOBSERVATIONAL
Enrollment

104

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

September 4, 2024

Study Completion Date

September 4, 2024

Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
Trial Locations (59)

D8224C00001

Research Site, Aichi

Research Site, Aomori

Research Site, Chiba

Research Site, Fukuoka

Research Site, Gunma

Research Site, Hiroshima

Research Site, Hokkaido

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Kagoshima

Research Site, Kanagawa

Research Site, Kyoto

Research Site, Miyagi

Research Site, Nagasaki

Research Site, Osaka

Research Site, Saitama

Research Site, Shiga

Research Site, Shizuoka

Research Site, Tokyo

Research Site, Wakayama

Unknown

Research Site, Aichi

Research Site, Akita

Research Site, Chiba

Research Site, Fukui

Research Site, Fukuoka

Research Site, Gifu

Research Site, Gunma

Research Site, Hiroshima

Research Site, Hokkaido

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Ishikawa

Research Site, Kagoshima

Research Site, Kanagawa

Research Site, Kochi

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Mie

Research Site, Miyagi

Research Site, Miyazaki

Research Site, Nagano

Research Site, Nagasaki

Research Site, Nara

Research Site, Niigata

Research Site, Numakunai

Research Site, Okayama

Research Site, Okinawa

Research Site, Osaka

Research Site, Ōita

Research Site, Saitama

Research Site, Shiga

Research Site, Shimane

Research Site, Shizuoka

Research Site, Tokyo

Research Site, Tottori

Research Site, Toyama

Research Site, Wakayama

Research Site, Yamagata

Research Site, Yamaguchi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT04872621 - Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation | Biotech Hunter | Biotech Hunter